FDA Cites Vanda for Misleading Website

In a rare warning letter from the FDA’s Office of Prescription Drug Promotion (OPDP), Vanda Pharmaceuticals was cited for failing to include any risk information on the product page of its website.
Source: Drug Industry Daily